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Abstract Octamer transcription factor 1 (OCT1) was found
to influence the genesis and progression of numerous cancers
except for colorectal cancer (CRC). This study tried to explore
the role of OCT1 in CRC and clarify the association between
its expression and patients’ clinical outcome. Transcriptional
and post-transcriptional expression of OCT1 was detected in
CRC cancerous tissues and paired normal mucosae by real-
time PCR as well as immunohistochemistry. Moreover, the
effect of OCT1 knockdown on CRC cell proliferation was
investigated both in vitro and in vivo using Cell Counting
Kit-8 assay, colony-forming assay, and mouse tumorigenicity
assay. Expression of OCT1 was found to be elevated in CRC.
Suppression of OCT1 significantly inhibited CRC cell prolif-
eration both in vitro and in vivo. Furthermore, upregulated
level of OCT1 was significantly associated with N stage, M
stage, and American Joint Committee on Cancer (AJCC)
stage (P=0.027, 0.014, and 0.002, respectively) as well as
differential degree (P=0.022). By using multivariate Cox haz-
ard model, OCT1was also shown to be a factor independently
predicting overall survival (OS; P=0.013, hazard ratio=
2.747, 95 % confidence interval 1.125 to 3.715) and disease-
free survival (DFS; P=0.004, hazard ratio=2.756, 95 % con-
fidence interval 1.191 to 4.589) for CRC patients. Our data
indicate that OCT1 carries weight in colorectal carcinogenesis
and functions as a novel prognostic indicator and a promising
target of anti-cancer therapy for CRC.
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Introduction
Colorectal cancer (CRC) is among the most prevalent cancers
in the world with annual new cases exceeding 100,000 [1]. In
spite of improvements of surgical and adjuvant treatment ap-
proaches, the long-term survival associated with its malignan-
cy is not satisfactory because of tumor recurrence and metas-
tasis [2, 3]. Thus, it is clinically valuable to identify genes that
function in germination and progression of CRC and their
efficacy for predicting prognosis.
Octamer transcription factor 1 (Oct1; gene symbol pou2f1),
a homeologous transcription factor of Oct4 [4], is comprised
in the Pit-Oct-Unc (Pit1, Oct1/2, Unc86) family, which pos-
sesses similar in vitro DNA binding specificity [5]. Through
binding to the canonical DNA motif (ATGCAAAT), OCT1
affects the transcription of a number of genes, like the immu-
noglobulin genes in B lymphocytes [6, 7], some interleukins
[8–10], and Pit-1 [11]. As a cis-factor, OCT1 is also required
in embryogenesis and maintaining stem cell function in vivo
[12]. Maddox J et al. [13] had highlighted new target genes
regulated by OCT1, such as Abcg2 and Abcb1, which are in
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accordance with its effects in stem cells. Besides, it has been
demonstrated that OCT1 was discovered to be over-expressed
in gastric cancer (GC) [14, 15], cervical cancer [16], and pros-
tate cancer [17, 18]. Additionally, by recognizing the CDX2
promoter, OCT1 is thought to boost malignancy of both pan-
creatic and intestine cell lines [19], and studies on p53-
deficient mice revealed that dysfunction of OCT1 restrains
in vitro tumor transformation and in vivo tumorigenicity via
metabolic procedure shift [20]. Nevertheless, in GC cells,
OCT1 was uncovered to lose the ability to activate CDX2
transcription despite that it could be recruited to the CDX2
promoter [15, 21]. In spite of recent studies exerting to eluci-
dating OCT1 as a cis-factor in malignancies, the role of OCT1
in colorectal carcinogenesis remains in its infancy and efforts
should be made to clarify the associations between OCT1
level and clinicopathological features of CRC.
These observations prompted us to investigate the expres-
sion of OCT1 in human colorectal cancer by utilizing real-
time PCR and immunohistochemistry (IHC), to figure out
the relationship between the OCT1 expression and clinical
parameters and explore its potential role in malignant colonic
hyperplasia both in vitro and in vivo.
Material and methods
Patients and clinical samples
The present research was sanctioned by the Institutional Re-
search Ethics Committee of Shanghai General Hospital, and
informed consent was signed by all the 98 patients, during
2007–2009, diagnosed with CRCs affirmed by clinical resec-
tion and pathology. No patients accepted either chemotherapy
or radiotherapy before the operation. The sixth American Joint
Committee on Cancer (AJCC) staging method was also ap-
plied for tumor staging by two pathologists. Cancer tissues
and adjacent normal mucosae (at least 10 cm from the primary
tumor) surgically removed from colon cancer patients were
immediately frozen in liquid nitrogen and stored at −80 °C.
Formalin-fixed matched noncancerous tissue, primary tumor
tissue, and metastatic lymph nodes were embedded in paraffin
for later immunohistochemistry (IHC) studies after a series of
dehydration.
RNA isolation and real-time PCR (qPCR)
Total RNA was extracted from cancerous tissues and paired
normal mucosae from 38 colon cancer patients according to
protocols of the manufacturer (TRIzol, Invitrogen, USA).
Complementary DNA was synthesized using 1 μg RNA by
RevertAid™First Strand cDNA Synthesis Kit (Fermentas,
USA). Quantitative PCR reaction was done on a ViiA™ 7
Real-Time PCR System (Life Technology, USA) with
SYBR® Premix DimerEraser™ (Perfect Real Time) (Takara,
Japan) in accordance with the manufacturer’s instructions.
Each experiment was performed in triplicate. Primer se-
quence s we r e a s f o l l ows : pou2 f1 f o rwa rd 5 ′ -
AAAAGAAATCAACCCACCAAGC-3′ and reverse 5′-
TGTGGTTCGGAACACTGATCG-3′, Gapdh forward 5′-
GGCCAAGGTCATCCATGACAA-3′ and reverse 5′-
TCTTCTGACACCTACCGGGGA-3′, Ki67 forward 5′-
TTCGCAAGCGCATAACCCA-3 ′ and reverse 5 ′-
AACCGTGTCACAGTGCCAAA-3′, and cyclin D1 forward
5′-GCTGCGAAGTGGAAACCATC-3′ and reverse 5′-
CCTCCTTCTGCACACATTTGAA-3′. The cycling condi-
tions were as follows: 95 °C, 2 min, 1 cycle, and 95 °C, 10s,
and 60 °C for 30 s followed by 30 s at 72 °C, 40 cycles.
Amplification product’s specificity was confirmed by the ex-
hibition of a singlet in the melting curve and electrophoresis.
IHC
After dewaxing and rehydrating in a graded series of ethanol,
sections (4 μm thick) were blocked with 3 % H2O2. Then,
slides were prepared for antigen retrieval process with
0.01 M sodium citrate solution (pH 6.0). Primary anti-
human rabbit polyclonal antibody against OCT1 (1:200;
Abcam, USA) was used for IHC staining, followed by incu-
bation with the horseradish peroxidase (HRP)-conjugated sec-
ondary detection antibody (Dako Cytomation, Glostrup, Den-
mark). Negative control was treated with PBS in the place of
anti-OCT1 antibody. Blinded evaluation of immunoreactivity
was executed independently by two pathologists. The mea-
surement was calculated by both the intensity and the area of
staining. Density of tintage was ranked as follows: 0, no stain-
ing; 1, mild staining; 2, moderate staining; and 3, intense
staining. Area of staining was sorted as follows: 0, no positive
cells; 1, <10 % of extent positive; 2, 10–50 % of extent pos-
itive; and 3, >50 % of extent positive. The final staining score
was obtained by multiplying the intensity score by the extent
score. The samples were classified into two groups by the final
scores: low (0–4) and high (5–9).
Cell culture and plasmids
Human colorectal cancer cells HCT116 and RKO were pur-
chased from American Type Culture Collection (Rockville,
MD). Cultured at 37 °C under a moist air with 5 % CO2, all
cell lines were maintained with Dulbecco’s modified Eagle me-
dium with 10 % FBS (Gibco, USA). The short hairpin RNA
(shRNA) plasmid for OCT1 and the control-shRNA plasmid
were purchased from Obio Technology (Shanghai, China).
For plasmid transfection, 4×104 cells per well in six-well plates
were cultured overnight and then transfected with plasmids uti-
lizing Lipofectamine 2000 (Invitrogen, CA). Stable clones of
HCT116 and RKO cells expressing OCT1 shRNA or control-
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shRNA were obtained by puromycin selection. The shRNA




Total protein was isolated using RIPA solution (Beyotime
Biotechnology, Jiangsu, China) according to the instructions.
BCA protein assay kit (Beyotime Biotechnology, Jiangsu,
China) was applied to measure the concentration of the pro-
tein. The same quantity of protein (30 μg) was spotted into
10 % SDS-polyacrylamide gel for electrophoresis and then
electrotransferred onto PVDF membranes. Membranes were
immersed at room temperature for 1 h in 5 % fat-free milk
solution with 0.1 % Tween 20, and then they were hatched
with antibodies against Oct1(1:500, Abcam) or Ki67 (1:100,
Abcam) or cyclin D1(1:100, Abcam) overnight, and then in-
cubation with HRP-tagged detection antibody (1:5000,
Abgent) was performed. Signal visualization was performed
using ECL reagent (Pierce Biotechnology, USA), and gray-
scale analysis was carried out by Quality One (Bio-Rad,
USA).
Proliferation assay
Cell Counting Kit-8 kit (Dojino, Japan) was used to evaluate
cell proliferation according to the manufacturer’s protocols. In
brief, 96-well plates were seeded with 2×103 cells per well in
triplicate. At the appropriate time (24, 48, 72, 96 h), each well
was incubated for 1.5 h with 10 μl CCK8 solution at 37 °C
with moist air with 5 % CO2. Then, absorbance at 450 nmwas
detected on a Gen5 microplate reader (BioTek, USA).
Colony formation assays
For plate colony formation assays, six-well plates were seeded
using 1000 log-phase cells per well and cultured at 37 °C with
5 % CO2 concentration atmosphere for 2 weeks. After fixed
by methanol for 15 min, the cells were then stained
with Giemsa solution for 20 min followed by colony
photographing and counting. All assays were indepen-
dently performed in triplicate.
Mice xenograft implantation
Stably transfected sh-OCT1 or sh-control vector of HCT116 or
RKO cells were injected subcutaneously in the flank of 6-week-
old nude mice (1×106 cells/mouse, five mice/group) as previ-
ously described [22]. All the procedures involving mice are in
accordance with the Shanghai Jiaotong University Affiliated
Shanghai General Hospital Animal Care guidelines. Endeavors
were made to the greatest extent to make animals suffer mini-
mally, or to abate the amount of animals to the best exploiture.
Tumor weight and bulk were measured every 7 days, and mice
were killed at 42 days after implantation.
Statistical analysis
Data from two experimental groups were analyzed by using
two-tailed Student’s t test. Pearson χ2 test or Fisher’s exact test
was used to compare categorical data. Kaplan–Meier method
was applied to calculate cumulative survival ratio. Hazard
Fig. 1 Levels of OCT1 in tumorous colon mucosae and matched normal
tissues. a Exhibition of OCT1 expression of colorectal carcinoma and
normal specimens from Hong colorectal statistics in Oncomine dataset
(t test, ***P<0.001); b statistical analysis of OCT1 mRNA levels in
normal tissue and CRC mucosa according to AJCC stage from TCGA
dataset (Mann–Whitney test, *P<0.05, **P<0.01); c relative expression
of OCT1 (gene symbol pou2f1) in 38 paired tumorous samples compared
with normal samples. Fold change was calculated by 2−ΔΔCT method; d
RT-qPCR product electrophoreses of OCT1 amplification in four paired
CRC tissues
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proportion of univariate and multivariate hazard for the clini-
cal factors of CRC patients was computed by establishing a
Cox hazardmodel. All data analyses were performed by SPSS
software 19.0 (SPSS, Chicago, IL, USA). A P value <0.05
was considered to be statistically significant.
Results
OCT1 expression levels are significantly upregulated
in human colorectal cancer
We first browse Oncomine (www.oncomine.org) to acquire
OCT1 expression in colorectal carcinoma and found that its
level was significantly high in tumor tissues compared with
the related normal mucosae (Fig. 1a). Further, we analyzed
data from The Cancer Genome Atlas (TCGA) according to
AJCC stage. The OCT1 level was augmented in stages II, III,
and IV but not in stage I (Fig. 1b). Then, 38 paired specimens
were analyzed for OCT1 messenger RNA (mRNA) level and
protein level; 19 (50 %) colorectal cancers revealed a more
than twofold accumulation in OCT1 mRNA expression com-
pared with related normal tissues (Fig. 1c, d). These data in-
dicated that OCT1 expression is commonly elevated in human
CRC.
OCT1 augment is associated with poor survival of CRC
patients
We further evaluated the relationship between OCT1 level and
numbers of clinicopathological parameters of CRC patients.
Among the 98 samples, 66 (67.35 %) showed negative stain-
ing in paired normal mucosae (Fig. 2a). In contrast, upregu-
lated OCT1 expression was apparent in colorectal tumors,
Fig. 2 Immunohistochemical staining for OCT1 expression and Kaplan–
Meier plots for survival by log-rank test. a Negative staining of OCT1 in
normal mucosa, ×200; b positive for OCT1 expression in moderately
differentiated cancer, ×200; c OCT1-positive of the poorly
differentiated tumor, ×200; d, e patients’ disease-free survival (DFS)
and overall survival (OS) according to OCT1 rank measured by
immunohistochemistry; cum survival was for cumulative survival
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with low staining in 40 (40.82%) specimens and high staining
in 58 (59.18 %) specimens. Summarization of associations
between OCT1 and clinical parameters is shown in Table 1.
Positive tintage was principally watched in the nucleus of
tumor cells in samples (Fig. 2b, c). Upregulated OCT1 level
was significantly associated with N stage (P=0.027), M stage
(P=0.014), AJCC stage (P=0.002), and differential grade
(P=0.022, Table 1). However, no association was found be-
tween OCT1 and sex, age, location, or vascular invasion. No-
tably, augmented expression of OCT1 is strongly associated
with poor survival of patients with CRC. The Kaplan–Meier
analysis revealed that patients with high levels of OCT1 pos-
sessed shorter overall survival (OS) time and disease-free sur-
vival (DFS) time than subjects with low levels of OCT1 (P=
0.004 and P=0.001, respectively, Fig. 2d, e). Survival analysis
using multivariate Cox model adjusted for AJCC stage, tumor
location, TNM stage, vascular invasion, and sex and age of
characters suggested strong association between OCT1 level
and shorter OS (P=0.013, hazard ratio (HR)=2.747, 95 %
confidence interval (CI) 1.125 to 3.715) and DFS (P=0.004,
HR=2.756, 95 % CI 1.191 to 4.589) as well (Table 2). These
findings consistently imply OCT1 as a potential prognostic
indicator for CRC.
Inhibition of colorectal cancer cell growth by shRNA
induced downregulation of OCT1 expression both in vitro
and in vivo
To determine the role of OCT1 in colorectal cancer cell prop-
agation, we treated HCT116 and RKO cells with OCT1
shRNA. We confirmed the efficacy of knockdown of OCT1
expression by using qPCR and Western blot (Fig. 3a). To
determine the effects of OCT1 knockdown on CRC cell prop-
agation, the expression of proliferation-related genes (Ki67;
cyclin D1) was detected by quantitative PCR (Fig. 3b). The
expression of both Ki67 and cyclinD1 mRNAwas downreg-
ulated in OCT1-shRNA cells. Next, we determined cell via-
bility by using CCK-8 assay and colony formation ability
(Fig. 3c, d). As shown in Fig. 3c, OCT1 knockdown was
associated with significantly decreased cell reproduction com-
pared with cells transfected with control-shRNA. Further-
more, OCT1 knockdown in CRC cells consistently reduced
the colony formation ability compared with mock-shRNA
cells (P<0.01). These in vitro data suggested that OCT1 con-
tributes to being critical in the propagation of colorectal cancer
cells. Thus, we determined to explore the capacity of multi-
plication of knockdown OCT1 colon cancer cells in vivo.
Compared with those injected with sh-control cells, mice
injected with sh-OCT1 cells exhibited tardive tumor morbid-
ity and reduced tumor growth (Fig. 4).
Discussion
OCT1, located in 1q24.2, is one of the first discovered tran-
scription factors (TFs) of POU orthologous family, and it not
only regulates levels of housekeeping genes as histone H2B
and tissue-specific gene as B29 [23] but also harbors the ca-
pacity of pro-proliferative function in tumors [24]. Although
the OCT1 transcription factor was found to be over-expressed
in many cancer cells [21, 25] and there exist considerable
investigations of its role in tumors [14–18], in CRCs, the
bio-functional and prognostic value of OCT1 has rarely been
expounded.
We uncovered aberrantly upregulated transcriptional ex-
pression of OCT1 in CRC using our own tissue bank as well
as two public databases (Oncomine database and TCGA da-
tabase) and confirmed its post-transcriptional level in the
Table 1 Correlation betweenOCT1 expression and clinicopathological
characteristics
OCT1 protein expression P value











T1 + T2 25 34
T3 + T4 15 24
N stage 0.027*
N0 27 26













P value derived from chi-square test or Fisher’s test
AJCC American Joint Committee on Cancer
*P<.005
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Table 2 Multivariate analysis of
metastasis-free survival (DFS)
and overall survival (OS) of 98
colon cancer patients
Variable Mutivariate analysis (DFS) Mutivariate analysis (OS)
P value HR CI (95 %) P value HR CI (95 %)
AJCC stage (I/II vs III/IV) 0.048* 1.911 1.005–3.634 0.019* 2.622 1.171–5.870
Differentiation (low vs high) 0.010* 2.004 1.184–3.392 0.017* 2.196 1.151–4.190
N (N1+N2 vs N0) 0.026* 2.359 1.107–5.027 0.001* 4.311 1.776–10.461
M (M1 vs M0) 0.016* 12.792 1.617–20.202 0.006* 3.363 2.706–4.138
OCT1 (low vs high) 0.004* 2.756 1.191–4.589 0.013* 2.747 1.125–3.715
AJCC American Joint Committee on Cancer, HR hazard ratio, CI confidence interval
*P<.005
Fig. 3 OCT1 knockdown
inhibits cancer cell proliferation. a
Western blot analyses of OCT1
level in stable knockdown
HCT116 and RKO cell lines.
Grayscale values were evaluated
(n=3, *P<0.05); b expression of
proliferation-related genes was
inhibited in OCT1 knockdown
cells according to real-time PCR
and western blot (n=3; *
P<0.05); c, d Effects of OCT1
knockdown on cell growth were
evaluated by Cell Counting Kit-8
assays (c) and plate colony
formation assays (d) (n=3; *
P<0.05, **P<0.01)
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established bank. Analysis of OCT1 level and patients’ clini-
cal outcomes suggested that those with high OCT1 expression
had poorer survival than those with low OCT1 expression.
Additionally, in accordance with discoveries of Perri et al. in
thyroid cancer cells [26], OCT1-interfering CRC cell lines
exhibited impaired proliferative potency both in vitro and
in vivo. These observations direct us to believe that OCT1
carries weight in colonic carcinogenesis and malignant pro-
gression and it is of great value as a predictor for prognoses of
colorectal cancer patients.
To the best of our knowledge, it is the first time that OCT1
transcription factor is implied as a promising predictor of the
prognoses of patients with colon cancer, and interfering OCT1
expression restrains hyperplasia in CRC oncogenesis. Inter-
estingly, Fang et al. found that, in gastric cancer, elevated
OCT1 level facilitated canonical extracellular-signal-
regulated kinase (ERK) signaling pathway by transactivating
synbindin which binds to ERK DEF domain, resulting in ac-
tivation of ERK substrates ELK1 and RSKwhich finally leads
to increased proliferative capacity and metastatic competency
[15]. Phosphorylation of ERK induces expression of cyclin
D1 and then promotes activation of E2F transcription factor
1 which appears to be essential in G0/G1-S stage transition
[27]. Similarly, OCT1 was discovered to be directly regulated
by STAT3 to reduce the expression of caspase 9, BAX, and
BAD via ERK and AKT activation to boost proliferation and
inhibit apoptosis in esophageal cancer cells [28]. Additionally,
OCT1 exhibits to be a regulator of epithelial–mesenchymal
transition of malignances [29, 30] and cancer stem cell’s re-
newal feature [13]. Judging by the observations aforemen-
tioned, targeting on OCT1 might be potentially viable for
anti-cancer therapy.
Tumor environment, which is a new hotspot in cancer re-
search realms and characterized by hypoxia, nutrition defi-
ciency, low pH, angiogenesis, and so forth [31], is believed
to occupy vital position in proliferation, invasion, and metas-
tasis [32]. Khairul et al. [33] uncovered that under insufficient
glucose metabolic stress, OCT1, activated by AMPK phos-
phorylation, negatively regulated miR451 to form a reciprocal
feedback loop to assist glioblastoma multiforme cells to sur-
vive nutrient/energy starvation. This enlightens us to investi-
gate on OCT1’s effects in CRC microenvironment in our fu-
ture study. Nonetheless, it should be noted that there are some
limitations of our study. First, the finite quantity of subjects
with comparatively limited follow-up period is not powerful
enough to clarify the role of OCT1 in CRC. Second, the ef-
fects of over-expressing OCT1 were not investigated in the
present study. Thus, further studies are required to confirm our
hypothesis that OCT1 is of favorable prognostic value and a
potential target for CRC therapy.
To conclude, this study focuses on the implication of OCT1
in CRC. OCT1 interference inhibits cell reproduction that
Fig. 4 Tumor weight and volume
of mice treated with sh-control or
sh-OCT1 colon cancer cells. a, c
Weights of tumor in mice injected
with sh-control or sh-OCT1
transfected HCT116 and RKO
cells, respectively; b, d tumor
sizes in mice injected with sh-
control or sh-OCT1 transfected
HCT116 and RKO cells,
respectively (n=5; tumor weight
of control group was arbitrarily
set to be 1, *P<0.05, **P<0.01,
***P<0.001)
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indicates that the trans-factor participates in colon tumorigen-
esis and progression. Moreover, abnormally recurrent ampli-
fication of OCT1 in CRC and analysis of its level and clini-
copathological parameters suggest it as a promising indepen-
dent predictor of clinical outcome of folks with bowel
malignancy.
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